Table 2. Paired drug concentration ratios by anatomic compartment on Day 7, immediately after pod-IVR removal (six participants in each group).
CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Data consist of medians (interquartile range) and only measurements within the analytical range of the assay are included.
| Pod-IVR Type | |||
|---|---|---|---|
| Analyte, Ratio | TDF | TDF-FTC | TDF-FTC-MVC |
| TFV,a CVF:VT | 6.6 (4.5–8.8) | 14 (4.2–42) | 14 (6.0–17) |
| FTC, CVF:VT | 17 (8.6–67) | 12 (5.8–17) | |
| MVC, CVF:VT | 3.5 (1.2–6.0) | ||
| TFV, VT:RF | 20 (17–20) | 6.2 (3.4–19) | 946 (559–2,396) |
| FTC, VT:RF | 5.6 (1.3–12) | 1,702 (404–3,565) | |
| MVC, VT:RF | 423 (101–855) | ||
| TFV,a CVF:RF | 87 (67–145) | 63 (25–100) | 12,763 (8,835–16,813) |
| FTC, CVF:RF | 83 (75–111) | 7,181 (6,978–40,726) | |
| MVC, CVF:RF | 644 (228–950) | ||
aMolar sum of paired TDF and TFV concentrations in CVF, reported as TFV.